Physician profile
Caryn Silver
NPI 1235112053
$709.31
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $16.79 · 2021: $11.92 · 2022: $177 · 2023: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $278.34 | 2019-2022 | |
| Astellas Pharma US INC | $59.47 | 2023 | Padcev |
| Novartis Pharmaceuticals Corporation | $57.93 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $49.05 | 2022-2023 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $29.30 | 2022 | |
| Daiichi Sankyo INC. | $27.68 | 2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $26.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $22.24 | 2023 | Keytruda |
| Abbvie INC. | $21.94 | 2023 | Venclexta |
| G1 Therapeutics, INC. | $18.16 | 2022 | |
| Eisai INC. | $18.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.78 | 2019 | |
| Apellis Pharmaceuticals, INC. | $13.47 | 2023 | Empaveli |
| Beigene USA, INC. | $13.17 | 2022 | |
| Adc Therapeutics America, INC. | $12.92 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11.95 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Amgen INC. | $11.67 | 2022 | |
| Pfizer INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caryn Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.